Anorexia News and Research

RSS

First Edition: October 19, 2012

Today's headlines include reports about how Medicare and women's health issues are playing in a number of House and Senate races.

19 Oct 2012

People in creative professions are treated more often for mental illness

People in creative professions are treated more often for mental illness than the general population, there being a particularly salient connection between writing and schizophrenia. This according to researchers at Karolinska Institutet in Sweden, whose large-scale registry study is the most comprehensive ever in its field.

17 Oct 2012

Vulnerability to ‘thin ideal’ may be genetic

Results from a study carried out in identical and nonidentical twins suggests that a woman’s risk for thin-ideal internalization may be genetic.

4 Oct 2012

Warning signs of eating disorders in children

It's a discussion that strikes fear in the hearts of most parents – adolescents expressing concern about their weight. According to statistics, 1 out of every 100 girls, between the ages of 10 and 20, struggles with anorexia and four percent of college-aged women have bulimia. So how can parents distinguish between normal adolescent insecurities and the start of a dangerous eating disorder?

19 Sep 2012

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Pfizer Oncology today announced that important data from its lung cancer and renal cell carcinoma (RCC) portfolios will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Vienna, Austria, September 28 - October 2, 2012.

18 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease.

4 Sep 2012

Aeterna Zentaris commences enrollment in AEZS-130 Phase 2A trial for cancer cachexia

Aeterna Zentaris Inc. today announced that a first patient has been recruited for a Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia.

28 Aug 2012

Controversial activities of pro-anorexic bloggers may have benefits

A groundbreaking new research study from Indiana University suggests there may be benefits to the controversial activities of "pro-ana" bloggers, the online community for people with eating disorders.

20 Aug 2012

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pfizer Inc. announced that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.

12 Aug 2012

Starvation drives methamphetamine-related death in fruit flies

A new study finds that fruit flies exposed to methamphetamine drastically reduce their food intake and increase their physical activity, just as humans do. The study, which tracked metabolic and behavioral changes in fruit flies on meth, indicates that starvation is a primary driver of methamphetamine-related death in the insects.

2 Aug 2012

Childhood obesity could be related to growing problems with infertility

A dramatic increase in childhood obesity in recent decades may have impacts that go beyond the usual health concerns - it could be disrupting the timing of puberty and ultimately lead to a diminished ability to reproduce, especially in females.

1 Aug 2012

Fatty acids normalize without help in girls with eating disorders

Omega-3 essential fatty acid supplementation is unnecessary for adolescent girls with eating disorders and weight-loss eating disorder, as levels normalize once they return to normal weight, say researchers.

26 Jul 2012

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that the first of two canine oncology products has received approval by regulators in both the U.S. and Canada.

24 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

Normalizing weight helps girls with eating disorders improve essential fatty acid status

A study of teenage girls with eating disorders has shown that reduced essential fatty acid levels returned to normal once the girls increased their weight to a healthy level.

18 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012